Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent - Eli Lilly ( NYSE:LLY )
On Friday, Eli Lilly and Company LLY revealed new results from the Phase 3b ADapt study of Ebglyss ( lebrikizumab ) , which will be presented at the Fall Clinical Dermatology Conference.
| Ticker |
Sentiment |
Impact |
|
LLY
|
Neutral
|
29 %
|
|
REGN
|
Neutral
|
19 %
|
|
SNY
|
Neutral
|
19 %
|
